• Daxor flagged new independent clinical data on blood-volume measurement in advanced heart failure, scheduled for presentation at HFSA 2026.
• Findings are expected to show the test can identify clinically meaningful fluid-status patterns missed by standard assessment methods.
• Management framed the data as support for broader adoption of its next-generation Blood Volume Analyzer across hospitals, aiming to reduce readmissions.
• The FDA 510(k)-cleared system is positioned as a faster workflow tool that uses a smaller blood draw, targeting easier routine clinical use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daxor Corporation published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.